Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
glucagon
Biotech
MetaVia’s GLP-1 sheds liver fat and body weight in phase 1
Encouraged by the data, MetaVia plans to start a phase 2 trial in alcohol-associated liver disease next year.
Nick Paul Taylor
Nov 5, 2026 9:52am
Lilly’s retatrutide tops Ozempic in ph. 3 diabetes showdown
Oct 28, 2026 7:45am
Zealand slides as Boehringer-partnered obesity drug underwhelms
Oct 1, 2026 6:15am
ADA: Tolerability questions linger for Boehringer's obesity drug
Jun 8, 2026 4:30am
ADA: Lilly offers deeper glimpse into triple-G obesity candidate
Jun 6, 2026 3:28pm
Lilly's $1.2B deal for Hanmi GLP-2 drug for short bowel syndrome
Jun 1, 2026 3:52am
